Geron (GERN) Short Percentage of Float

View and export this data going back to 1996. Start your Free Trial

What is Geron Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Geron's Short Percentage of Float

For the Biotechnology subindustry, Geron's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Geron's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Geron's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Geron's Short Percentage of Float falls into.

Geron (GERN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geron Corp (NAS:GERN) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

GON:Germany

Address

919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404

Website

https://www.geron.com

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. the company operates as a single segment, the development of therapeutic products for oncology.

Executives

Michelle Robertson	officer: EVP, Chief Financial Officer	C/O MOMENTA PHARMACEUTICALS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Elizabeth G. O'farrell	director	932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Scott Alan Samuels	officer: EVP, Chief Legal Officer	919 E. HILLSDALE BLVD., SUITE 250, FOSTER CITY CA 94404
V Bryan Lawlis	director
Susan Molineaux	director	C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080
John A Scarlett	director, officer: Chief Executive Officer	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Andrew J Grethlein	officer: EVP, Technical Operations	651 GATEWAY BLVD STE 950, SOUTH SAN FRANCISCO CA 94080
Olivia Kyusuk Bloom	officer: Controller, Chief Acctg Off	C/O GERON CORP, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
John F Mcdonald	director	C/O GERON CORPORATION, 919 EAST HILLSDALE BLVD., SUITE 250, FOSTER CITY CA 94404
Faye Feller	officer: EVP, Chief Medical Officer	919 EAST HILLSDALE BOULEVARD, SUITE 250, FOSTER CITY CA 94404
Anil Kapur	officer: EVP, Corp Strategy & CCO	275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Melissa Kelly	officer: VP, Oncology	230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Dawn Carter Bir	director	C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DRIVE, SUITE 150, IRVING TX 75063
Aleksandra Rizo	officer: EVP, Chief Medical Officer	C/O GERON CORPORATION, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Robert J. Spiegel	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025